DAAG | Dopamine Agonist Action Group

Skip to Content

Aims and Objectives

Types of Dopamine Agonists

Impulsive and Compulsive behaviour

Augmentation in RLS/PLMD

Dopamine Agonist Withdrawal Syndrome

Other side effects

Health Unlocked Communities

Petition

DAAG Press Releases

Impulsive Podcast

Media Appearances

Aims and Objectives

Types of Dopamine Agonists

Impulsive and Compulsive behaviour

Augmentation in RLS/PLMD

Dopamine Agonist Withdrawal Syndrome

Other side effects

Health Unlocked Communities

Petition

DAAG Press Releases

Impulsive Podcast

Media Appearances

Aims and Objectives

Folder: Resources

Types of Dopamine Agonists

Impulsive and Compulsive behaviour

Augmentation in RLS/PLMD

Dopamine Agonist Withdrawal Syndrome

Other side effects

Health Unlocked Communities

Folder: Campaigns

Petition

DAAG Press Releases

Impulsive Podcast

Media Appearances

Campaign team

Emma Sanderson-Nash, Chair of the Dopamine Agonist Action Group (DAAG)

Emma Sanderson-Nash

Freddie Waite, Founding Member of the Dopamine Agonist Action Group (DAAG)

Freddie Waite

Julie Gould, Founding Member of the Dopamine Agonist Action Group (DAAG)

Julie Gould

David Williams, Founding Member of the Dopamine Agonist Action Group (DAAG)

David Williams

DAAG is a patient-led campaign working to improve awareness, informed consent, research, safeguarding and support for those affected by dopamine agonist side effects.

Have you or a loved one been affected by dopamine agonist side effects?

Share your story | Join our mailing list | Contact us